RUO
In 2006, the U.S. FDA added UGT1A1*28 genotype information to the drug label for Irinotecan and to assess the potential value of genotyping of UGT1A1∗28 in patients before starting treatment with irinotecan to reduce the risk of severe toxicity.
In 2006, the U.S. FDA added UGT1A1*28 genotype information to the drug label for Irinotecan and to assess the potential value of genotyping of UGT1A1∗28 in patients before starting treatment with irinotecan to reduce the risk of severe toxicity.
Clopidogrel ( Plavix), relating to disease: atherosclerotic events in patients with stroke, myocardial infarction or peripheral arterial vascular disease (e.g., myocardial infarction, stroke, or other death due to vascular disease)